Search results
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Barrons.com· 2 days agoPfizer Currently Dominates Market FDA approval of Merck’s new pneumococcal vaccine, Capvaxive, tees...
MSD competes with Pfizer in pneumococcal vaccine market after FDA approval
Pharmaceutical Technology via Yahoo Finance· 2 days ago"MSD competes with Pfizer in pneumococcal vaccine market after FDA approval " was originally created...
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks via Yahoo Finance· 3 days agoNovavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 7 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 7 days ago“We are extremely disappointed that these results did not demonstrate the relative improvement in...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 6 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Market Watch· 2 days ago“We’ll provide protection that’s broader than anything that’s out there,” Art Hirt, senior vice...
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Zacks via Yahoo Finance· 2 days agoMerck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 7 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 7 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...